Cures & Capital
Cures & Capital
Podcast Description
Hello and welcome to Cures & Capital - the podcast on value creation in biotech and pharma.Together, we are going to dive deep into the world of biotech and pharma to tackle the holy grail - how do we improve return on investment from drug innovation and deliver transformative therapies to patients, efficiently and sustainably.Hosted by Martin Slezak & Simon BirksøDisclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.
Podcast Insights
Content Themes
The podcast explores topics around drug research and development (R&D), investment strategies, and business models in the pharmaceutical industry, with episodes addressing issues like declining ROI in drug innovation and decision-making in R&D, featuring in-depth discussions with experts in the field.
Hello and welcome to Cures & Capital – the podcast on value creation in biotech and pharma.
Together, we are going to dive deep into the world of biotech and pharma to tackle the holy grail – how do we improve return on investment from drug innovation and deliver transformative therapies to patients, efficiently and sustainably.
Hosted by Martin Slezak & Simon Birksø
Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.
How did China become a serious force in global biotech in just over a decade?
This is the insider story of China's biotech boom!
Dr. Leon 'Jun' Tang, founding partner of InScienceWeTrust BioAdvisory, joins Cures & Capital to unpack the rise of Chinese biopharma.
From talent migration and government planning to innovation in ADCs and the challenges of commercialization.
Chapters
00:00 – Introduction & Leon’s global background
01:13 – Guest introduction – Leon 'Jun' Tang
05:35 – Impact of Chinese biotech innovation at biomedical conferences
14:30 – The wave of China-to-West licensing deals
18:00 – Understanding the rise of China's biotech industry
22:00 – Push & pull: why Chinese scientists leave the West
24:40 – Government strategy & capital markets as biotech catalysts
34:30 – Could India, Africa, or the Middle East replicate China’s path?
37:25 – How do Chinese biotech industry parks look in practice?
46:46 – How fast and cost-effective are Chinese biotech companies?
52:05 – Impact of Chinese biotech on the US and EU
59:26 – When will China have its own Pfizer or Eli Lilly?
01:05:30 – Closing reflections by Martin & Simon
If you want to connect with us – we would love to hear from you:
Linkedin: https://www.linkedin.com/company/cures-capital-podcast
If you prefer to get the episodes as just audio, you can also get the podcast from Spotify and Apple Podcasts.
If you want to connect with Leon:
https://www.linkedin.com/in/leontangbiotech/
Here's a link to Leon's article in Nature Reviews Drug Discovery:
Analysis of China-to-West pharmaceutical licensing deals in 2024
Nature Reviews Drug Discovery 24, 411-412 (2025)
doi: https://doi.org/10.1038/d41573-025-00068-0
Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.